A novel approach for the prediction of species-specific biotransformation of xenobiotic/drug molecules by the human gut microbiota

The human gut microbiota is constituted of a diverse group of microbial species harbouring an enormous metabolic potential, which can alter the metabolism of orally administered drugs leading to individual/population-specific differences in drug responses. Considering the large heterogeneous pool of human gut bacteria and their metabolic enzymes, investigation of species-specific contribution to xenobiotic/drug metabolism by experimental studies is a challenging task. Therefore, we have developed a novel computational approach to predict the metabolic enzymes and gut bacterial species, which can potentially carry out the biotransformation of a xenobiotic/drug molecule. A substrate database was constructed for metabolic enzymes from 491 available human gut bacteria. The structural properties (fingerprints) from these substrates were extracted and used for the development of random forest models, which displayed average accuracies of up to 98.61% and 93.25% on cross-validation and blind set, respectively. After the prediction of EC subclass, the specific metabolic enzyme (EC) is identified using a molecular similarity search. The performance was further evaluated on an independent set of FDA-approved drugs and other clinically important molecules. To our knowledge, this is the only available approach implemented as ‘DrugBug’ tool for the prediction of xenobiotic/drug metabolism by metabolic enzymes of human gut microbiota.

[1]  K. Shindo,et al.  Omeprazole induces altered bile acid metabolism , 1998, Gut.

[2]  V. P. Butler,et al.  Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. , 1981, The New England journal of medicine.

[3]  B. Sidorenko,et al.  [The place of cardiac glycosides in the treatment of chronic heart failure. Part II. Results of small studies]. , 2005, Kardiologiia.

[4]  Dan S. Tawfik,et al.  Enzyme promiscuity: evolutionary and mechanistic aspects. , 2006, Current opinion in chemical biology.

[5]  L. Benet,et al.  Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  Axel Drefahl,et al.  CurlySMILES: a chemical language to customize and annotate encodings of molecular and nanodevice structures , 2011, J. Cheminformatics.

[7]  B. Vallee,et al.  Digitalis metabolism and human liver alcohol dehydrogenase. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Jun Jiang,et al.  The mechanism of enzymatic and non-enzymatic N-oxide reductive metabolism of cyadox in pig liver , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  Wei Xie,et al.  RFECS: A Random-Forest Based Algorithm for Enhancer Identification from Chromatin State , 2013, PLoS Comput. Biol..

[10]  M. Blaut,et al.  Degradation of quercetin‐3‐glucoside in gnotobiotic rats associated with human intestinal bacteria , 2000, Journal of applied microbiology.

[11]  M. J. Siegman,et al.  Myosin light chain phosphorylation does not modulate cross-bridge cycling rate in mouse skeletal muscle. , 1983, Science.

[12]  John C Lindon,et al.  Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism , 2009, Proceedings of the National Academy of Sciences.

[13]  P. Cotter,et al.  Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ , 2013, Therapeutic advances in gastroenterology.

[14]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[15]  Károly Héberger,et al.  Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? , 2015, Journal of Cheminformatics.

[16]  Stein Aerts,et al.  Identification of High-Impact cis-Regulatory Mutations Using Transcription Factor Specific Random Forest Models , 2015, PLoS Comput. Biol..

[17]  J. Caldwell,et al.  The demethylation of methamphetamine by intestinal microflora , 1973, The Journal of pharmacy and pharmacology.

[18]  S. Copley Enzymes with extra talents: moonlighting functions and catalytic promiscuity. , 2003, Current opinion in chemical biology.

[19]  P. Turnbaugh,et al.  Developing a metagenomic view of xenobiotic metabolism. , 2013, Pharmacological research.

[20]  Scott Boyer,et al.  Reaction Site Mapping of Xenobiotic Biotransformations , 2007, J. Chem. Inf. Model..

[21]  Eleazar Eskin,et al.  Genetic and environmental control of host-gut microbiota interactions , 2015, Genome research.

[22]  Andrzej J. Bojarski,et al.  The influence of negative training set size on machine learning-based virtual screening , 2014, Journal of Cheminformatics.

[23]  W. Klangpetch,et al.  The Effect of Low-Pressure Carbonation on the Heat Inactivation of Escherichia coli , 2011, Bioscience, biotechnology, and biochemistry.

[24]  S. Pettersson,et al.  Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA , 2004, Nature Immunology.

[25]  V. Mathan,et al.  Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. , 1989, Gut.

[26]  D. Williamson,et al.  Tissue and bacterial splitting of sulphasalazine. , 1983, Clinical science.

[27]  M. Ding,et al.  Effects of cyadox and olaquindox on intestinal mucosal immunity and on fecal shedding of Escherichia coli in piglets. , 2006, Journal of animal science.

[28]  K. Hult,et al.  Enzyme promiscuity: mechanism and applications. , 2007, Trends in biotechnology.

[29]  Dong-Hyun Kim Gut Microbiota-Mediated Drug-Antibiotic Interactions , 2015, Drug Metabolism and Disposition.

[30]  G. Sousa,et al.  Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes , 1991, Fundamental & clinical pharmacology.

[31]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[32]  CHUN WEI YAP,et al.  PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..

[33]  S. Akimoto,et al.  Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. , 1997, Pharmacogenetics.

[34]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[35]  Y. Bao,et al.  Melamine-Induced Renal Toxicity Is Mediated by the Gut Microbiota , 2013, Science Translational Medicine.

[36]  P. Turnbaugh,et al.  Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta , 2013, Science.

[37]  P. Turnbaugh,et al.  Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics , 2014, Gut microbes.

[38]  C. Toyoshima,et al.  A Structural View on the Functional Importance of the Sugar Moiety and Steroid Hydroxyls of Cardiotonic Steroids in Binding to Na,K-ATPase* , 2013, The Journal of Biological Chemistry.

[39]  Matthew R. Redinbo,et al.  Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme , 2010, Science.

[40]  Y. Tao,et al.  Metabolism of cyadox by the intestinal mucosa microsomes and gut flora of swine, and identification of metabolites by high-performance liquid chromatography combined with ion trap/time-of-flight mass spectrometry. , 2011, Rapid communications in mass spectrometry : RCM.

[41]  Bas E Dutilh,et al.  Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. , 2014, Omics : a journal of integrative biology.

[42]  S. Kitamura,et al.  The Role of Mammalian Intestinal Bacteria in the Reductive Metabolism of Zonisamide , 1997, The Journal of pharmacy and pharmacology.

[43]  Fredrick Devadoss,et al.  Analysis and visual summarization of molecular dynamics simulation , 2014, Journal of Cheminformatics.

[44]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[45]  Sanjay Joshua Swamidass,et al.  RS-WebPredictor: a server for predicting CYP-mediated sites of metabolism on drug-like molecules , 2013, Bioinform..

[46]  E. Mardis,et al.  An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.

[47]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[48]  H. Neu,et al.  Digoxin-inactivating bacteria: identification in human gut flora. , 1983, Science.

[49]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[50]  Vineet K. Sharma,et al.  Woods: A fast and accurate functional annotator and classifier of genomic and metagenomic sequences. , 2015, Genomics.

[51]  S. Mazmanian,et al.  Intestinal Microbes in Inflammatory Bowel Diseases , 2012 .

[52]  Vineet K. Sharma,et al.  16S Classifier: A Tool for Fast and Accurate Taxonomic Classification of 16S rRNA Hypervariable Regions in Metagenomic Datasets , 2015, PloS one.

[53]  Eric Vivier,et al.  The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide , 2013, Science.

[54]  Max Kuhn,et al.  The caret Package , 2007 .

[55]  B. Goldin,et al.  Metabolism of drugs by microorganisms in the intestine. , 1974, The American journal of clinical nutrition.

[56]  D. Herschlag,et al.  Catalytic promiscuity and the evolution of new enzymatic activities. , 1999, Chemistry & biology.

[57]  Ian H. Witten,et al.  The WEKA data mining software: an update , 2009, SKDD.

[58]  M. Spatz,et al.  Role of Intestinal Microorganisms in Determining Cycasin Toxicity , 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[59]  Wei Jia,et al.  The influence of gut microbiota on drug metabolism and toxicity , 2016, Expert opinion on drug metabolism & toxicology.

[60]  J. V. Houdt,et al.  Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[61]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[62]  Abdul W Basit,et al.  The gastrointestinal microbiota as a site for the biotransformation of drugs. , 2008, International journal of pharmaceutics.

[63]  P. Macdonald,et al.  Digoxin in heart failure and cardiac arrhythmias , 2003, The Medical journal of Australia.

[64]  Robert C. Glen,et al.  FAst MEtabolizer (FAME): A Rapid and Accurate Predictor of Sites of Metabolism in Multiple Species by Endogenous Enzymes , 2013, J. Chem. Inf. Model..